Form 4: Axsome Therapeutics Director Acquires Stock Options in Lieu of Cash Compensation
SEC Form 4 Filing
Director Mark E. Saad acquired 1,519 stock options in Axsome Therapeutics, Inc. in lieu of cash compensation earned in 2023.
Summary
- On February 27, 2024, Mark E. Saad, a director of Axsome Therapeutics, Inc., acquired 1,519 stock options.
- These options were received in lieu of cash compensation earned in 2023 and are immediately exercisable.
- The exercise price of the options is $84.
- The options expire on February 26, 2034.
Sentiment
Score: 6
Explanation: The document itself is neutral, simply reporting a transaction. The sentiment is slightly positive as it reflects a director's increased stake in the company.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This is a standard practice for compensating board members and executives in publicly traded companies, aligning their interests with those of shareholders.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment, as it indicates a director's belief in the company's future prospects.
Key Dates
| Date | Description |
|---|---|
| 02/27/2024 | Date of transaction: Mark E. Saad acquired 1,519 stock options. |
| 02/26/2034 | Expiration date of the stock options. |
| 02/29/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.